Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNP3794 in NRAS/KRAS Mutated Solid Tumors
NCT05187858Phase 1Completed
- Sponsor
- Lupin Limited
- Start
- Sep 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of BI 3011441 in solid tumor, sponsored by Lupin Limited. Primary endpoint: Number of subjects with dose limiting toxicities (DLTs) at each dose level during the first cycle at Day 28. Started Sep 2020; status: completed.
02
Drugs
BI 3011441
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05187858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05187858.